PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshemophilia a
MeSH D006467 - hemophilia a
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D025861:Inherited blood coagulation disorders
27 Companies
2 Drugs
$
Success rate
D020147:Coagulation protein disorders
0 Companies
0 Drugs
Success rate
D006474:Hemorrhagic disorders
1 Company
1 Drug
$
Success rate
D006467: 
Hemophilia a
12 Companies
15 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
RocheEmicizumab Hemlibra  2018-02-23 $4,779.09 M Q4/22-Q3/23 
BayerOctocog alfa Helixate NexGen  2000-08-04   
Octocog alfa Iblias  2016-02-18   
Octocog alfa Kogenate Bayer  2000-08-04   
Octocog alfa Kovaltry  2016-02-18   
PfizerNonacog alfa BeneFIX  1997-08-27 $424 M Y2023 
Moroctocog alfa ReFacto  1999-04-13 $230 M Y2023 
TakedaOctocog alfa Advate  2004-03-02   
GenentechEmicizumab Hemlibra  2017-11-16   
Orphan MedicalEfmoroctocog alfa Elocta  2015-11-18   
Novo NordiskTuroctocog alfa Esperoct  2019-06-20   
Turoctocog alfa NovoEight  2013-11-13   
Eptacog alfa (activated) NovoSeven  1996-02-23   
BioMarin PharmaceuticalValoctocogene roxaparvovec Roctavian  2023-06-29 $16.338 M Q3/23-Q3/24 
CSL BehringLonoctocog alfa Afstyla  2017-01-04   
Human coagulation factor viii, Human von willebrand factor Voncento  2013-08-12   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
86%
19/22
Phase 2
91%
20/22
Phase 3
83%
29/35
Approved: 14Overall Success rate: 65%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Roche
Emicizumab,
Antithrombin iii,
Lampalizumab,
NXT007,
Rfviia,
Articular,
Demand
Bayer
Octocog alfa,
Antithrombin iii,
Concizumab,
Tifacogin,
Choline alfoscerate,
Serine,
Befovacimab,
Bevifimod,
Coagulation factor viia recombinant human,
Coagulation factor ix human,
Bay-1093884,
Rfviia,
Articular,
Arm1,
Arm2,
Demand
Pfizer
Moroctocog alfa,
Nonacog alfa,
Marstacimab,
Albumin,
Concizumab,
Tifacogin,
Befovacimab,
Bevifimod,
Edetic acid,
Coagulation factor ix human,
Bay-1093884,
Diluent,
Articular,
Arm1,
Demand
Takeda
Octocog alfa,
Coagulation factor viia recombinant human,
Rfviia
Genentech
Emicizumab,
Coagulation factor viia recombinant human,
Corticoids,
Rfviia,
Articular,
Demand
Orphan Medical
Efmoroctocog alfa,
Benzocaine,
Albumin,
Bevifimod,
Coagulation factor ix human,
Rfviiifc,
Articular,
Demand
Novo Nordisk
Turoctocog alfa,
Eptacog alfa (activated),
Concizumab,
Edrecolomab,
Alfacalcidol,
EPTACOG ALFA PEGOL (ACTIVATED),
Coagulation factor viia recombinant human,
Coagulation factor ix human,
Rfviia,
Articular,
Arm1,
Arm2,
Demand,
Mim8
BioMarin Pharmaceutical
Valoctocogene roxaparvovec,
Bevifimod,
Corticoids
CSL Behring
Lonoctocog alfa,
Human coagulation factor viii,
Human von willebrand factor,
Human coagulation factor viii/von willebrand factor complex,
Albumin,
Antithrombin iii,
Bevifimod,
Coagulation factor viia recombinant human,
Coagulation factor ix human,
Endocrine,
Optivate,
Rfviia,
Articular,
Demand
Baxalta
Rurioctocog alfa pegol,
Benzocaine,
Albumin,
Concizumab,
Tifacogin,
Sodium chloride,
Bevifimod,
Coagulation factor viia recombinant human,
Coagulation factor ix human,
Diluent,
Octaplex,
Rfviia,
Articular,
Demand
Octapharma
Simoctocog alfa,
Benzocaine,
Bevifimod,
Coagulation factor viia recombinant human,
Coagulation factor ix human,
Octa101,
Rfviia,
Demand
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use